UNSPSC 51151623: Bornaprine

This classification denotes an antimuscarinic agent with the molecular formula C21H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9M363FGA7J, chemically known as 2-phenylbicyclo(2.2.1)heptane-2-carboxylic acid, 3-(diethylamino)propyl ester but generally known as bornaprine, which bears US NIH Compound Identifier 30160. European Medicines Agency schedules Bornaprine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05874MIG.

UNSPSC 51151623 Bornaprine, a Commodity code, covers pharmaceutical products and drug-related supplies that state and local governments procure for community health, emergency response, and harm-reduction initiatives. Recent solicitations show state and local agencies buying naloxone (an opioid antagonist) and drug deactivation systems for public health programs, alongside exploratory procurement for direct-to-manufacturer pharmaceutical supply arrangements. The code captures both routine pharmaceutical procurement—unit-based orders placed through competitive bidding—and strategic sourcing initiatives where agencies seek to reshape supply chains and pricing relationships with pharmaceutical manufacturers and vendors.

Issuing bodies under this code include county health departments and state health and human services agencies. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023 (note: the source shows a discrepancy between the posted date of June 30, 2026, and the original bid deadline of July 26, 2023). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—a market-intelligence phase preceding formal RFP issuance. Activity is concentrated in Florida and Texas, with procurement spanning traditional health department supply acquisition and emerging state-level initiatives to establish direct manufacturer relationships outside conventional pharmacy benefit manager and group purchasing organization channels.